CompletedPhase 2NCT02738801

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Galapagos NV
Principal Investigator
Ann Fieuw, MD
Galapagos NV
Intervention
GLPG1690 600 mg QD(drug)
Enrollment
23 enrolled
Eligibility
40 years · All sexes
Timeline
2016 – 2017

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02738801 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials